Copyright © Inderes 2011 - present. All rights reserved.

Bioretec

0.15 EUR

-5.96 %

1,715 following
Corporate customer

BRETEC

First North Finland

Medical Equipment & Services

Health Care

-5.96 %
-47.92 %
-75.00 %
-76.11 %
-88.37 %
-93.22 %
-93.48 %
-
-94.67 %

Bioretec operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio includes, for example, implants for pediatric and adult orthopedics and other materials for bone and soft tissue injuries. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic region.

Read more
Market cap
4.62M EUR
Turnover
9.13K EUR
P/E (adj.) (26e)
-1.72
EV/EBIT (adj.) (26e)
-0.92
P/B (26e)
1.02
EV/S (26e)
1.7
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
0.32 EUR
Updated
15.02.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 16.02.2026

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
27.3
2026

Extraordinary general meeting '26

8.5
2026

General meeting '26

15.5
2026

Business review Q1'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
These rights issues are a mix of psychology and mathematics. Mathematically, one could argue, as already warned in the thread, that if the offering results in 1.5 billion additional shares to raise 15 million, that is 1 cent per share. Often, the stock price also drops to that mathematical...
3/13/2026, 9:53 AM
by Vino Pino
4
You can think of it as being forced to participate in the share issue now. Otherwise, all your old holdings go down the toilet and you can forget about the whole company. For example, Duell has destroyed its balance sheet with losses, and those who participated in the IPO have lost...
3/13/2026, 8:31 AM
by Nordman09
4
Personally, I am 100% disappointed in the company’s performance, both in terms of its spending and its ability to commercialize its products. The millions from previous rounds have been wasted in record time without any results whatsoever. I personally don’t believe that the company...
3/13/2026, 7:33 AM
by Jopinaattori
4
On the other hand, I would be interested to know how you think the company should raise funding in this situation, with bankruptcy knocking at the door? The biggest problem here is that the company has hired poor CEOs, made bad distribution agreements, failed to ensure the growth...
3/13/2026, 7:16 AM
by Expaco_b
4
A couple of months ago Inderes Tuukka Paavola on nimitetty Bioretecin talousjohtajaksi - Inderes Bioretec Oy Yhtiötiedote 15.1.2026 kello 17:30 EETBiohajoavien ortopedisten implanttien edelläkävijä Bioretec Oy, on nimittänyt Tuukka Paavolan (DI, CFA) talousjohtajaksi 20. tammikuuta...
3/13/2026, 2:28 PM
by Vino Pino
2
I have exactly the same thoughts. Absolutely incomprehensible bungling that has wiped out 92% of the market value in a year. I also thought a share issue was coming and that I would probably participate. However, those share issue terms were the final red flag (I know, if you subscribe...
3/13/2026, 11:17 AM
by Kim Blomqvist
2
Thank you @Vino_Pino ! I completely missed this. I’ve even been checking LinkedIn from time to time to see what Paavola’s situation is after the sudden departure from NGH. And today was so strange; while I was writing my previous message, I had already double-checked several times...
3/13/2026, 3:02 PM
by Balle Ramsted - pienehkö kasvusijoittaja nupullaan
1
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.